Ikarian Capital, LLC Larimar Therapeutics, Inc. Transaction History
Ikarian Capital, LLC
- $606 Million
- Q4 2024
A detailed history of Ikarian Capital, LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 58,526 shares of LRMR stock, worth $159,775. This represents 0.04% of its overall portfolio holdings.
Number of Shares
58,526
Previous 58,528
0.0%
Holding current value
$159,775
Previous $383,000
41.78%
% of portfolio
0.04%
Previous 0.07%
Shares
10 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$58 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$17.6 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$16.5 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$12.7 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$11.3 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $118M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...